TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
• Accurate risk stratification is crucial for optimal AML treatment.
• The role of TP53 mutations in AML prognosis is increasingly recognized.

Purpose of the Study:

• To determine the frequency of TP53 mutations across European LeukemiaNet 2022 AML risk categories.
• To evaluate the prognostic significance of a TP53 mutated variant allelic fraction below 10%.
• To assess the impact of specific chromosomal abnormalities and myelodysplasia-related gene mutations in TP53-mutated AML.

Main Methods:

• Analysis of TP53 mutation frequency within defined AML risk groups.
• Correlation of TP53 variant allelic fraction (<10%) with clinical outcomes.
• Prognostic evaluation of genetic aberrations (e.g., -7, -5/del(5q), -17/abn(17p), complex/monosomal karyotype) in conjunction with TP53 status.

Main Results:

• TP53 mutation frequency varied across European LeukemiaNet 2022 AML risk classifications.
• A TP53 mutated variant allelic fraction <10% was assessed for its prognostic relevance.
• The prognostic impact of specific genetic abnormalities was analyzed in the context of TP53 mutation status.

Conclusions:

• TP53 mutation frequency is a key factor within AML risk stratification.
• Low variant allelic fraction of TP53 mutations may have prognostic implications.
• Combined genetic abnormalities with TP53 mutations significantly influence AML prognosis.